{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269468","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.016748+00:00","generated_at":"2026-05-16T23:44:11.220986+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026","bullets":["Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.","Net loss $14.7M ($1.09/share) vs $11.6M loss in Q3 2024.","First patients dosed in two triplet arms of PIKture-01: fulvestrant+ribociclib and trastuzumab+tucatinib.","Initial clinical data from monotherapy and fulvestrant arms now expected Q1 2026.","Next-gen PI3Kα pan-mutant inhibitor candidate selection announced; more details Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269468","json":"https://secwatch.observer/filing/0001193125-25-269468.json","markdown":"https://secwatch.observer/filing/0001193125-25-269468.md","text":"https://secwatch.observer/filing/0001193125-25-269468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312525269468/0001193125-25-269468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312525269468/okur-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:44:11.220986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}